<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40913984</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1618-095X</ISSN><JournalIssue CitedMedium="Internet"><Volume>147</Volume><PubDate><Year>2025</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Phytomedicine : international journal of phytotherapy and phytopharmacology</Title><ISOAbbreviation>Phytomedicine</ISOAbbreviation></Journal><ArticleTitle>Integrated metabolomics and network pharmacology analysis of Yulan Jiangtang capsules in diabetic nephropathy.</ArticleTitle><Pagination><StartPage>157189</StartPage><MedlinePgn>157189</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phymed.2025.157189</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0944-7113(25)00828-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Diabetic nephropathy (DN), a serious diabetic complication, currently has limited treatment options. Yulan Jiangtang capsules (YL) are a clinically approved traditional Chinese medicine formula for glycemic control and diabetes-related complications. Nevertheless, the underlying mechanisms of their therapeutic effects remain incompletely elucidated.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study employed a comprehensive strategy involving network pharmacology, metabolomics, and experimental validation to investigate the potential mechanisms of YL in DN.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Firstly, initial investigations combined UPLC-MS technology with network pharmacology to systematically identify the key components, core targets, and associated pathways of YL. Secondly, experimental rats were fed a high-fat/high-glucose diet for 4 weeks, followed by diabetes induction using STZ injection (35 mg/kg; success criteria: random glucose &#x2265;16.7 mmol/l at 72 h). 2 weeks later, Diabetic nephropathy rats (confirmed by elevated urinary protein and microalbumin) were randomized into five groups (n = 16/group): Model, Met + Irb (150+15.75 mg/kg), and YL (189, 378, 756 mg/kg). YL and Met+Itb were orally administered for 10 weeks, twice a day. FBG, GHb, and some indicators reflecting renal function were determined. Kidney tissue pathology was evaluated using H&amp;E staining, PAS staining, and TEM. Thirdly, the functional role of the AGEs-RAGE-NF-&#x3ba;B signaling pathway was experimentally validated. Finally, non-targeted urinary metabolomics was performed using UHPLC-QE-MS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Network pharmacology results showed 119 active compounds identified from YL could effectively treat DN through multiple mechanisms, including blood sugar control, anti-inflammation, anti-oxidation, and angiogenesis. Animal experiments confirmed that YL demonstrated significant anti-diabetic and renoprotective effects in DN rats, notably improving glycemic control and ameliorating kidney damage. Among them, high-dose YL could significantly reduce blood glucose levels (p &lt; 0.05), and improved kidney function by decreasing FBG, GHb, 24-hour urine protein, mALB, SCR, BUN and UACR (p &lt; 0.05 or p &lt; 0.01). It also decreased MDA, IL-1&#x3b2;, IL-6, and TNF-&#x3b1;, elevated SOD, and inhibited the expressions of AGEs, RAGE and NF-&#x3ba;B in the kidney of DN rats (p &lt; 0.05). Additionally, YL treatment could reverse the increase in five metabolites (including 2'-Deoxycytidine, octopine, palmitic acid, N-Carbobenzyloxy-glycine, and N-Acetylneuraminic acid) and the decrease in four metabolites (including &#x3b1;-Linolenic acid, l-Citrulline, l-tyrosine, and N-l-gamma-Glutamyl-l-leucine) in the urine of DN rats. These metabolites are involved in pathways such as phenylalanine/tyrosine/tryptophan biosynthesis, phenylalanine metabolism, &#x3b1;-linolenic acid metabolism, and arginine biosynthesis.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">YL treatment significantly mitigates kidney injury in DN rats by modulating the AGEs-RAGE axis and restoring metabolic homeostasis, thereby attenuating oxidative stress and inflammation. This research provides an experimental basis for the clinical application of YL in treating DN.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier GmbH.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Xiaochun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, 102488, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Lan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, 102488, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Haoran</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, 102488, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jiayao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, 102488, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Hanwen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, 102488, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Yanping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, 102488, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Jiahui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, 102488, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shuofeng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, 102488, China. Electronic address: zhangsf@bucm.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, 102488, China. Electronic address: fangf@bucm.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Phytomedicine</MedlineTA><NlmUniqueID>9438794</NlmUniqueID><ISSNLinking>0944-7113</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002214">Capsules</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003928" MajorTopicYN="Y">Diabetic Nephropathies</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="Y">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091484" MajorTopicYN="N">Network Pharmacology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="N">Metabolomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002214" MajorTopicYN="N">Capsules</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003921" MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AGEs/RAGE signaling pathway</Keyword><Keyword MajorTopicYN="N">Diabetic nephropathy</Keyword><Keyword MajorTopicYN="N">Metabolomics</Keyword><Keyword MajorTopicYN="N">Network pharmacology</Keyword><Keyword MajorTopicYN="N">Yulan Jiangtang capsules</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>23</Day><Hour>3</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>7</Day><Hour>0</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>6</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40913984</ArticleId><ArticleId IdType="doi">10.1016/j.phymed.2025.157189</ArticleId><ArticleId IdType="pii">S0944-7113(25)00828-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>